A Mount Sinai-led team of researchers has enhanced an artificial intelligence (AI)-powered algorithm to analyze video ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Decreased blood flow of the optic nerve head (MA, MV, and MT measurements) was significantly correlated with increased OSA ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

Postmenopausal sleep issues contribute to a sharp decline in sleep quality among older women, beginning at approximately 51 ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Endothelial inflammation, as measured by E-selectin, was significantly associated with hypoxemia measures, even after adjusting for BMI.